SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US Listed > Medical - Drugs >

Spectrum Pharmaceutecals, Inc. (SPPI)

SPPI RSS Feed
Add SPPI Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 6/21/2017 8:53:46 AM - Followers: 75 - Board type: Free - Posts Today: 0

http://www.spectrumpharm.com/

http://finance.yahoo.com/q/ks?s=SPPI+Key+Statistics

Company Presentation

http://www.sppirx.com/704-corporate-presentation.html

Spectrum Development Pipeline/Portfolio

Fusilev® (Levoleucovorin) for injection FDA Approved on April 29, 2011 for Use in Patients with Advanced Metastatic Colorectal Cancer and FDA Approved on March 7, 2008 for High-Dose Methotrexate Rescue Therapy in Osteosarcoma.
Zevalin® (ibritumomab tiuxetan), an FDA-Approved, Proprietary, Biological Drug for Indolent Non-Hodgkin's Lymphoma.
Belinostat a novel HDAC inhibitor in late stage clinical development for Peripheral T-cell Lymphoma, and other Solid Tumors (including Carcinoma of Unknown Primary, etc.)
Apaziquone, one of our lead development candidates, is a synthetic bio-reductive prodrug that is being investigated in the treatment of non-invasive bladder cancer, and began two Phase 3 studies in 2007.Spectrum also has three drugs in the Phase 2 stage of development: Ozarelix, for the treatment of prostate cancer and Ortataxel, for the treatment of taxane-refractory tumors.
The Company has three drugs in the Phase 1 stage of development: SPI-1620, an adjunct to chemotherapy, Elsamitrucin, which will target advanced solid tumors and Lucanthone, a chemotherapy sensitizer in the treatment of recurrent, malignant brain tumors.
Other drugs in development include SPI-014, used in the treatment of hyperphosphotemia in end stage renal disease (ESRD), and SPI-205 for chemotherapy induced neuropathy.

Recent News (Zevalin):

http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=632354
http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=632346

.  

 

SPPI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SPPI News: Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Pres... 06/19/2017 07:00:00 AM
SPPI News: Current Report Filing (8-k) 06/16/2017 04:37:00 PM
SPPI News: Statement of Changes in Beneficial Ownership (4) 06/15/2017 05:14:13 PM
SPPI News: Statement of Changes in Beneficial Ownership (4) 06/15/2017 05:11:37 PM
SPPI News: Statement of Changes in Beneficial Ownership (4) 06/15/2017 04:57:47 PM
PostSubject
#1683   "Top 4 Small-Cap Stocks for 2017" Investopedia repost antihama 06/21/17 08:53:46 AM
#1682   PR today on Pralatrexate/Romidepsin in Relapsed/Refractory Lymphoid Malignancies. antihama 06/19/17 08:33:57 AM
#1681   Some thoughts on Puma’s neratinib. The Advisory Panel antihama 06/18/17 10:49:08 AM
#1680   Annual Meeting voting 8k antihama 06/16/17 08:00:37 PM
#1679   Folotyn being tested in combo with PD-L1 inhibitor antihama 06/16/17 06:43:21 PM
#1678   Just commented on an article about Coherus's biosim antihama 06/13/17 02:09:31 PM
#1677   The future playing field/market potential for Rolontis revisited. antihama 06/13/17 01:09:33 PM
#1676   No one wants to go near EGFR Exon antihama 06/09/17 12:15:45 PM
#1675   Pfizer’s EGFR TKI lung cancer candidate, dacomitinib was antihama 06/08/17 09:34:32 PM
#1674   My take on the Jeffries 2017 Global Healthcare antihama 06/06/17 09:48:28 PM
#1673   Zevalin mentioned as an ADC drug being sold antihama 06/02/17 04:26:32 PM
#1672   The future playing field/market potential for Rolontis. An antihama 05/26/17 03:21:42 PM
#1671   Investopedia recommendation of SPPI and the Golden Cross. antihama 05/23/17 07:43:49 AM
#1670   Regarding the combo trial of poziotinib w T-DM1 antihama 05/22/17 05:39:12 PM
#1669   I think we just dodged a bullet. I antihama 05/17/17 10:06:09 PM
#1668   Thanks stugwins. I try to present facts but antihama 05/17/17 03:23:04 PM
#1667   Keep it up antihama. There are plenty who stugwins 05/17/17 02:27:07 PM
#1666   Im reading his posts, just not replying. Didn't Fenway32 05/17/17 01:52:03 PM
#1665   You are essentially talking to yourself as I antihama 05/15/17 04:04:45 PM
#1664   'antihama...I used to be a long term holder pearsby09 05/15/17 03:35:50 PM
#1663   I am not disagreeing with that assumption, after antihama 05/15/17 09:22:28 AM
#1662   You did not consider the Raj discount.....The market stugwins 05/14/17 12:55:51 PM
#1661   Spectrum’s MC is WAY LOW compared to MacroGenics antihama 05/13/17 11:03:04 AM
#1660   Just to clarify, when I refer to 'halted' antihama 05/12/17 08:10:36 AM
#1659   EGFR exon 20 insertions is one tough cookie antihama 05/11/17 09:00:03 PM
#1658   Initially stumped by a new SPI-2012 PK study antihama 05/10/17 06:11:39 PM
#1657   Correction- I didn't mean 'laxative' in the previous antihama 05/06/17 08:40:37 AM
#1656   Tracking the poziotinib dosing changes for my sanity. antihama 05/05/17 02:06:32 PM
#1655   Puma's Senior Vice President, Regulatory Affairs and Project antihama 05/04/17 06:08:28 PM
#1654   Stream of consciousness thoughts on 2017 Q1 CC antihama 05/03/17 10:03:15 AM
#1653   Evomela little over $6 mil! That's half what stugwins 05/03/17 10:00:06 AM
#1652   Spectrum Pharma is getting out of their shell! antihama 04/27/17 08:10:29 AM
#1651   Spectrum Through Resistance -- Technicals Hit Extreme Strength! antihama 04/26/17 08:32:14 PM
#1650   Time to Improve Transplant Access for Seniors with antihama 04/26/17 05:48:23 PM
#1649   "There're no approved treatments for PTCL in Europe." antihama 04/25/17 01:58:09 PM
#1648   Projected Headline- Spectrum Pharma Beats on Q1 Revenue antihama 04/25/17 08:34:54 AM
#1647   A ‘bon sentiment’ to the announced Q1 CC antihama 04/25/17 08:03:11 AM
#1646   7.5% increase in S/P Thursday coincided with Jefferies antihama 04/24/17 08:51:41 AM
#1645   To laugh or cry after reading about neratinib antihama 04/19/17 07:54:48 PM
#1644   antihama 04/10/17 09:05:57 PM
#1643   Regarding your Q on Evomela’s market share potential antihama 04/10/17 08:26:11 PM
#1642   Mystery solved regarding Wed's 30c decline. It coincided antihama 04/09/17 08:21:24 AM
#1641   Here's an Analyst Research article from postanalyst.com on antihama 04/08/17 08:23:24 AM
#1640   Spectrum Pharma owns ~20% of CASI. Here's a antihama 04/06/17 07:35:26 PM
#1639   Seeing Poziotinib’s sales potential through Tagrisso’s eyes. Tagrisso antihama 04/01/17 09:46:13 AM
#1638   Of course the $64,000 question regarding Poziotinib in antihama 03/30/17 09:05:29 AM
#1637   Ha! There is no truth I work for antihama 03/30/17 08:48:11 AM
#1636   Wow. The P2 Poziotinib in EGFR Exon antihama 03/29/17 12:14:24 PM
#1635   Revising my sales projection for Evomela upwards to antihama 03/24/17 12:42:37 PM
#1634   Sanofi and Regeneron were hit w a CRL antihama 03/22/17 08:51:19 PM
PostSubject